Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company, as the stock is now down over 10% in the past one-month time frame.
In the last 30-day frame, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Halozyme Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Better-ranked med-biomed gene stocks include Cambrex Corp. (CBM), China Biologic Products, Inc. (CBPO) and Gilead Sciences Inc. (GILD). All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment